CRISPR Therapeutics Statistics
Share Statistics
CRISPR Therapeutics has 86.36M
shares outstanding. The number of shares has increased by 1.01%
in one year.
| Shares Outstanding | 86.36M |
| Shares Change (YoY) | 1.01% |
| Shares Change (QoQ) | 0.49% |
| Owned by Institutions (%) | 76.49% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 30,336 |
| FTD / Avg. Volume | 1.41% |
Short Selling Information
The latest short interest is 21.32M, so 24.69% of the outstanding
shares have been sold short.
| Short Interest | 21.32M |
| Short % of Shares Out | 24.69% |
| Short % of Float | 28.07% |
| Short Ratio (days to cover) | 13.58 |
Valuation Ratios
The PE ratio is -9.07 and the forward
PE ratio is -8.97.
CRISPR Therapeutics's PEG ratio is
-0.07.
| PE Ratio | -9.07 |
| Forward PE | -8.97 |
| PS Ratio | 94.87 |
| Forward PS | 1.3 |
| PB Ratio | 1.72 |
| P/FCF Ratio | -22.95 |
| PEG Ratio | -0.07 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for CRISPR Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 22.07,
with a Debt / Equity ratio of 0.12.
| Current Ratio | 22.07 |
| Quick Ratio | 22.07 |
| Debt / Equity | 0.12 |
| Debt / EBITDA | -0.5 |
| Debt / FCF | -1.55 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $89,058.52 |
| Profits Per Employee | $-931,938.93 |
| Employee Count | 393 |
| Asset Turnover | 0.02 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 3.59M |
| Effective Tax Rate | -0.99% |
Stock Price Statistics
The stock price has increased by -31% in the
last 52 weeks. The beta is 1.87, so CRISPR Therapeutics's
price volatility has been higher than the market average.
| Beta | 1.87 |
| 52-Week Price Change | -31% |
| 50-Day Moving Average | 38.04 |
| 200-Day Moving Average | 44.16 |
| Relative Strength Index (RSI) | 54.71 |
| Average Volume (20 Days) | 2,150,138 |
Income Statement
In the last 12 months, CRISPR Therapeutics had revenue of 35M
and earned -366.25M
in profits. Earnings per share was -4.34.
| Revenue | 35M |
| Gross Profit | 37.31M |
| Operating Income | -466.57M |
| Net Income | -366.25M |
| EBITDA | -447.31M |
| EBIT | -466.57M |
| Earnings Per Share (EPS) | -4.34 |
Full Income StatementBalance Sheet
The company has 298.26M in cash and 223.69M in
debt, giving a net cash position of 74.56M.
| Cash & Cash Equivalents | 298.26M |
| Total Debt | 223.69M |
| Net Cash | 74.56M |
| Retained Earnings | -1.37B |
| Total Assets | 2.17B |
| Working Capital | 1.75B |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -142.77M
and capital expenditures -1.9M, giving a free cash flow of -144.68M.
| Operating Cash Flow | -142.77M |
| Capital Expenditures | -1.9M |
| Free Cash Flow | -144.68M |
| FCF Per Share | -1.71 |
Full Cash Flow StatementMargins
Gross margin is 106.61%, with operating and profit margins of -1333.05% and -1046.43%.
| Gross Margin | 106.61% |
| Operating Margin | -1333.05% |
| Pretax Margin | -1036.19% |
| Profit Margin | -1046.43% |
| EBITDA Margin | -1278.02% |
| EBIT Margin | -1333.05% |
| FCF Margin | -413.36% |
